Table 1 Clinical and laboratory features of enrolled individuals
| Â | DM | HCs |
|---|---|---|
Number | 30 | 26 |
Age (years) | 45.3 ± 12.5 | 44.8 ± 10.7 |
Sex (male to female) | 10:16 | 10/16 |
Disease duration (months) | 3 (1–48) | NA |
Major clinical features | ||
 Skin rash (%) | 100% (30/30) | NA |
 Muscular weakness (%) | 60% (18/30) | NA |
 Arthralgia (%) | 37% (11/30) | NA |
 Dysphagia (%) | 20% (6/30) | NA |
 ILD (%) | 53% (16/30) | NA |
 Malignancy (%) | 3% (1/30) | NA |
 MYOACT score (mean ± SD) | 0.213 ± 0.072 | NA |
Major laboratory features | ||
 CK (IU/L), median (IQR) | 326 (130–4852) | NA |
 LDH (IU/L), median (IQR) | 262 (40–2953) | NA |
 MSA positive (%) | 80% (24/30) | NA |
 Anti-MDA5+ (%) | 38% (9/24) | NA |
 Anti-TIF1-r+ (%) | 25% (6/24) | NA |
 Anti-NXP2+ (%) | 8% (2/24) | NA |
 Anti-Mi-2+ (%) | 8% (2/24) | NA |
 Anti-PL-7+ (%) | 13% (3/24) | NA |
 Anti-EJ+ (%) | 8% (2/24) | NA |
 CD4 T cells (cells/μl) | 421 (287–1377) | NA |
 CD8 T cells (cells/μl) | 209 (60–681) | NA |